Search clinical trials for: Cancer Type Specific Immunotherapy

Total 126845 results

Hideho Okada, MD, PhD
National Cancer Institute (NCI); California Institute for Regenerative Medicine...

Recruiting

Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells

Glioblastoma | Recurrent Glioblastoma | EGFR Gene Mutation | MGMT-Unmethylated Glioblastoma

United States
GERCOR - Multidisciplinary Oncology Cooperative...

Recruiting

Watch-and-Wait Approach With Dostarlimab in Localized dMMR/MSI-H Gastric Cancer: GERCOR Phase II Study (DEWI)

Gastric Adenocarcinoma | Adenocarcinoma - GEJ

France
University Health Network, Toronto
Takara Bio Inc.

Recruiting

Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL

Relapsed or Refractory Chronic Lymphocytic Leukemia | Relapsed or Refractory Small Lymphocytic Lymphoma | Relapsed or Refractory CD19+ B-cell Lymphoma

Canada
Celldex Therapeutics

Recruiting

A Study of CDX-585 in Patients With Advanced Malignancies

Renal Cell Carcinoma | Head and Neck Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Fallopian Tube Cancer | Cholangiocarcinoma | Non-small Cell Lung Cancer | Primary Peritoneal Carcinoma | Hepatic Cancer | Bladder Urothelial Carcinoma | Other Solid Tumors

United States
Fudan University

Recruiting

Peripheral Blood Neoantigen Specific T Cells Predict the Efficacy of Immunotherapy for Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Katy Peters, MD, PhD
Servier

Not yet recruiting

ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas (ViCToRy)

Low Grade Glioma of Brain

United States
Marengo Therapeutics, Inc.

Recruiting

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors (START-001)

Neoplasms | Urogenital Neoplasms | Neoplasms by Site | Carcinoma | Epstein-Barr Virus Infections | Advanced Solid Tumors | Vulvar Neoplasms | Vulvar Diseases | Abdominal Neoplasm | Lung Neoplasm | Papillomavirus Infection | Genital Neoplasm, Female

United States, Canada
Sun Yat-sen University
Akeso Pharmaceuticals, Inc.

Recruiting

Cadonilimab (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | Nasopharyngeal Cancer

China
Mark Stein

Recruiting

Study of ADXS-504 Immunotherapy for Recurrent Prostate Cancer

Recurrent Prostate Cancer

United States
Atara Biotherapeutics

Recruiting

A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases

Lymphoproliferative Disorders | Leiomyosarcoma | Stem Cell Transplant Complications | Solid Organ Transplant Complications | Epstein-Barr Virus (EBV)-Associated Diseases | EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD) | Allogeneic Hematopoietic Cell Transplant | EBV+ Sarcomas | EBV+ Lymphoproliferative... and other conditions

United States, Austria, Belgium, France, Italy, Spain, United Kingdom
Jonsson Comprehensive Cancer Center
Parker Institute for Cancer Immunotherapy; California Institute for Regenerative... and other collaborators

Recruiting

Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Breast Cancer | Neuroendocrine Tumors | Lung Adenocarcinoma | Metastatic Melanoma | Head and Neck Squamous Cell Carcinoma | Refractory Malignant Solid Neoplasm | Thyroid Cancer | Pheochromocytoma | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Pathologic Stage IIIC Cutaneous Melanoma... and other conditions

United States
Melanoma Institute Australia
Bristol-Myers Squibb

Recruiting

Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study) (ABC-X)

Melanoma Stage Iv

Australia, Norway
Fred Hutchinson Cancer Center
Mustang Bio

Recruiting

A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic... and other conditions

United States
Alaunos Therapeutics

Active, not recruiting

Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors

Gynecologic Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Cholangiocarcinoma | Adenocarcinoma of Lung | Endometrial Cancer | Non-small Cell Lung Cancer | Ovarian Carcinoma | Squamous Cell Lung Cancer | Ovary Neoplasm | Adenosquamous Cell Lung Cancer

United States
University of Washington
National Cancer Institute (NCI); Imago BioSciences, Inc., a subsidiary of Merck...

Active, not recruiting

Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer

Extensive Stage Lung Small Cell Carcinoma | Limited Stage Lung Small Cell Carcinoma

United States
Seattle Children's Hospital
The Evan Foundation; Ben Towne Center for Childhood Cancer Research

Active, not recruiting

Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01

Neuroblastoma | Ganglioneuroblastoma

United States
University of Florida
Accelerate Brain Cancer Cure; Lyla Nsouli Foundation

Active, not recruiting

Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I) (BRAVO)

Brain Stem Glioma | Diffuse Intrinsic Pontine Glioma (DIPG)

United States
Fred Hutchinson Cancer Center
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Terminated

huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia

Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Adult Acute Lymphoblastic Leukemia | Refractory Diffuse... and other conditions

United States
Fred Hutchinson Cancer Center
HighPass Bio, Inc.

Suspended

HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Acute Myeloid Leukemia | Leukemia | Chronic Myelomonocytic Leukemia | Juvenile Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Refractory... and other conditions

United States
Baylor College of Medicine
National Cancer Institute (NCI); The Methodist Hospital Research Institute; Center... and other collaborators

Active, not recruiting

3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN (GRAIN)

Neuroblastoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia

Recurrent Adult Burkitt Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Post-Transplant Lymphoproliferative Disorder | Recurrent Chronic Lymphocytic Leukemia | Recurrent Follicular Lymphoma and other conditions

United States
Providence Health & Services
Eli Lilly and Company

Active, not recruiting

ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer

Rectal Adenocarcinoma

United States
University Children's Hospital Tuebingen
German Cancer Research Center; University Hospital Tuebingen; Universität Tübingen

Completed

Patient-individualized Peptide Vaccination Based on Tumor-specific Mutations in Children and Young Adults With Primary/Relapsed ALL

Primary/Relapsed Acute Lymphoblastic Leukemia (ALL) of Childhood, Adolescents and Young Adults

Germany
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia

B Acute Lymphoblastic Leukemia | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia

United States
MedImmune LLC

Completed

MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.

Carcinoma | Metastatic Pancreatic Adenocarcinoma

United States, Spain, Australia, Norway
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); Juno Therapeutics, Inc.

Completed

Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute:Dana- Farber/Children's Hospital

Active, not recruiting

T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

Relapsed B-Cell Acute Lymphoblastic Leukemia

United States
Dana-Farber Cancer Institute
National Cancer Institute (NCI); Massachusetts General Hospital; Brigham and...

Completed

A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

United States
Tessa Therapeutics

Completed

A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients (VANCE)

Nasopharyngeal Carcinoma

United States, Taiwan, Malaysia, Singapore, Thailand
Gritstone bio, Inc.

Completed

A Screening Study Targeting Tumor-specific Antigens

Metastatic Colorectal Cancer | Stage II/III Colon Cancer

United States
Atara Biotherapeutics
Merck Sharp & Dohme LLC

Terminated

Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)

Nasopharyngeal Carcinoma | Nasopharyngeal Neoplasms | Epstein-Barr Virus Infections | Epstein-Barr Viraemia | Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); AstraZeneca; Juno Therapeutics, Inc.; MedImmune...

Terminated

JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); EMD Serono

Terminated

Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma

Stage IV Merkel Cell Carcinoma AJCC v7 | Merkel Cell Polyomavirus Infection

United States
Inovio Pharmaceuticals
University of Pennsylvania

Completed

Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Cancer

United States
Shenzhen Geno-Immune Medical Institute
Shenzhen Children's Hospital; Shenzhen Hospital of Southern Medical University

Unknown

Immunotherapy Based on Antigen-specific Immune Effector Cells Targeting Neurofibromatosis or Schwannomatosis

Cancer

China
Baylor College of Medicine
The Methodist Hospital Research Institute

Withdrawn

T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR)

Hepatocellular Carcinoma | Hepatoblastoma
National Cancer Institute (NCI)

Completed

A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas

Rhabdomyosarcoma | Ewing's Sarcoma

United States
GlaxoSmithKline

Completed

Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma

Melanoma

France, Italy, Germany, Netherlands, Switzerland, United Kingdom, Austria, Australia
GlaxoSmithKline

Completed

Evaluation of a New Anti-cancer Immunotherapy in Adult Acute Myeloid Leukemia Patients With a Suboptimal Clinical Response to Induction Chemotherapy

Leukaemia, Myelocytic, Acute

Germany, France, United States
GlaxoSmithKline

Completed

Evaluation of a New Anti-cancer Immunotherapy After Chemotherapy in Adult Patients With Acute Myeloid Leukemia (AML)

Leukaemia, Myelocytic, Acute

United States, France
Dartmouth-Hitchcock Medical Center
University of Vermont

Terminated

Derivation of Tumor Specific Hybridomas

Glioblastoma
New York Medical College
Johns Hopkins University; M.D. Anderson Cancer Center; Baylor College of Medicine and other collaborators

Terminated

Allogeneic Stem Cell Transplantation With Adoptive Immunotherapy in Epstein-Barr Virus Positive Recurrent/Refractory Hodgkins Lymphoma

Hodgkins Lymphoma

United States
University Hospital Tuebingen

Unknown

Adjuvant Antigen Specific Immunotherapy in Patients With Advanced Renal Cell Carcinoma Using Tumor Associated Peptides (UroRCC)

Renal Cell Cancer | Advanced Renal Cell Cancer
M.D. Anderson Cancer Center
National Cancer Institute (NCI); National Institutes of Health (NIH)

Withdrawn

Adoptive Therapy Using Antigen-Specific CD4 T-Cells

Melanoma | Sarcoma
National Cancer Institute (NCI)

Completed

Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines

Lymphoma | Follicular Lymphoma | B Cell Lymphoma

United States
Dana-Farber Cancer Institute
Brigham and Women's Hospital

Completed

Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

United States
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
The First People's Hospital of Hefei; Hefei Binhu Hospital

Unknown

CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor

Hepatocellular Carcinoma | Malignant Glioma of Brain | Non-small Cell Lung Cancer | Gastric Carcinoma | Colorectal Carcinoma | Pancreatic Carcinoma | Triple-Negative Invasive Breast Carcinoma

China
University of Alabama at Birmingham

Withdrawn

Immunotherapy for Lymphoproliferative Diseases Associated With Epstein-Barr Virus in Patients Who Have Undergone Organ Transplants

Lymphoma | Leukemia

United States
Second Military Medical University

Unknown

Radical Surgery Followed by Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen for the Treatment of Hepatocellular Carcinoma

Liver Cancer

China
National Cancer Institute (NCI)

Terminated

Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With Renal Cell Carcinoma

Renal Cell Carcinoma

United States

Search clinical trials for: Cancer Type Specific Immunotherapy

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zimbabwe

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations